caa a22 4500 465789706 CHVBK 20180323112020.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF00171987 doi (NATIONALLICENCE)springer-10.1007/BF00171987 Evaluation of menogaril in renal cell carcinoma [Elektronische Daten] A Southwest Oncology Group phase II study (8504) [Ronald Stephens, Phyllis Goodman, E. Crawford, Connie Spicer, Bruce Lowe, Frederick Ahmann, Robert Chapman, Ronald Natale] Summary: The Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m2 i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma. During the early stage of the trial two partial responses were seen in the first 20 treated patients, and an additional 36 evaluable patients were studied. Three of 56 (5%) evaluable patients achieved partial responses. Significant white cell toxicity was observed. Mild or moderate degrees of thrombocytopenia, gastrointestinal side effects, alopecia and phlebitis occurred. No cardiac toxicity was noted. The low response rate suggests that menogaril in this dose schedule has no role in the treatment of patients with advanced metastatic renal cancer. Kluwer Academic Publishers, 1990 menogaril nationallicence renal cell carcinoma nationallicence Stephens Ronald University of Kansas Medical Center, USA aut Goodman Phyllis Southwest Oncology Group Statistical Center, USA aut Crawford E. University of Colorado, USA aut Spicer Connie University of Kansas Medical Center, USA aut Lowe Bruce Oregon Health Sciences University, Arizona, USA aut Ahmann Frederick University of Arizona, USA aut Chapman Robert Henry Ford Hospital, USA aut Natale Ronald University of Michigan Medical Center, USA aut Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S69-S71 0167-6997 8<S69 1990 8 10637 https://doi.org/10.1007/BF00171987 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171987 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Stephens Ronald University of Kansas Medical Center, USA aut NATIONALLICENCE 700 1- Goodman Phyllis Southwest Oncology Group Statistical Center, USA aut NATIONALLICENCE 700 1- Crawford E. University of Colorado, USA aut NATIONALLICENCE 700 1- Spicer Connie University of Kansas Medical Center, USA aut NATIONALLICENCE 700 1- Lowe Bruce Oregon Health Sciences University, Arizona, USA aut NATIONALLICENCE 700 1- Ahmann Frederick University of Arizona, USA aut NATIONALLICENCE 700 1- Chapman Robert Henry Ford Hospital, USA aut NATIONALLICENCE 700 1- Natale Ronald University of Michigan Medical Center, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S69-S71 0167-6997 8<S69 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer